Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)‘s stock had its “hold” rating reaffirmed by J P Morgan Chase & Co in a report issued on Thursday.

A number of other research firms have also recently weighed in on MNTA. Goldman Sachs Group, Inc. (The) initiated coverage on Momenta Pharmaceuticals in a report on Thursday, September 28th. They issued a “neutral” rating and a $18.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $26.00 target price on shares of Momenta Pharmaceuticals in a research report on Thursday, August 3rd. Barclays PLC cut their target price on Momenta Pharmaceuticals from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Wednesday. BidaskClub lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Finally, Zacks Investment Research raised Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $15.44.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 10.26% during mid-day trading on Thursday, reaching $13.55. 1,854,855 shares of the company traded hands. The firm’s 50 day moving average price is $16.83 and its 200-day moving average price is $15.81. Momenta Pharmaceuticals has a 52-week low of $10.75 and a 52-week high of $19.90. The company’s market capitalization is $1.00 billion.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.50). The firm had revenue of $23.57 million during the quarter, compared to analysts’ expectations of $24.64 million. Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. Momenta Pharmaceuticals’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.31) EPS. Equities analysts predict that Momenta Pharmaceuticals will post ($1.53) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) Stock Rating Reaffirmed by J P Morgan Chase & Co” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/05/momenta-pharmaceuticals-inc-mnta-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.

In related news, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total transaction of $678,743.01. Following the sale, the president now directly owns 286,121 shares of the company’s stock, valued at approximately $5,444,882.63. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $15.07, for a total value of $62,028.12. Following the sale, the president now directly owns 269,231 shares in the company, valued at $4,057,311.17. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,663 shares of company stock worth $1,414,498. 4.40% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. raised its position in shares of Momenta Pharmaceuticals by 14.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 834 shares in the last quarter. Tortoise Investment Management LLC acquired a new stake in shares of Momenta Pharmaceuticals during the 2nd quarter valued at approximately $114,000. Pinebridge Investments L.P. raised its position in shares of Momenta Pharmaceuticals by 4.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 363 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Momenta Pharmaceuticals during the 1st quarter valued at approximately $158,000. Finally, BNP Paribas Arbitrage SA raised its position in shares of Momenta Pharmaceuticals by 13.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 1,570 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.